Sandra Calvin Sells 5,375 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 5,375 shares of Travere Therapeutics stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $62.33, for a total transaction of $335,023.75. Following the sale, the chief accounting officer owned 42,353 shares of the company’s stock, valued at approximately $2,639,862.49. The trade was a 11.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Price Performance

Shares of NASDAQ:TVTX opened at $62.76 on Friday. The firm has a market capitalization of $5.92 billion, a price-to-earnings ratio of -136.43 and a beta of 1.05. The company has a debt-to-equity ratio of 24.58, a current ratio of 4.05 and a quick ratio of 3.99. The business’s 50 day simple moving average is $61.76 and its 200-day simple moving average is $48.60. Travere Therapeutics, Inc. has a 12 month low of $22.06 and a 12 month high of $68.73.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03. The firm had revenue of $169.58 million during the quarter, compared to the consensus estimate of $157.27 million. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.Travere Therapeutics’s quarterly revenue was up 48.2% on a year-over-year basis. During the same period last year, the business posted $0.13 EPS. As a group, equities analysts forecast that Travere Therapeutics, Inc. will post -0.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on TVTX. Piper Sandler reiterated an “overweight” rating on shares of Travere Therapeutics in a research report on Monday, August 17th. TD Cowen upped their target price on Travere Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright upped their price objective on Travere Therapeutics from $57.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. Wells Fargo & Company boosted their target price on shares of Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a research note on Friday, June 12th. Finally, Weiss Ratings downgraded shares of Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $68.00.

Institutional Trading of Travere Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in shares of Travere Therapeutics by 53.4% during the 2nd quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after acquiring an additional 211 shares during the period. Corient Private Wealth LP increased its position in Travere Therapeutics by 1.4% during the second quarter. Corient Private Wealth LP now owns 48,125 shares of the company’s stock worth $2,734,000 after purchasing an additional 648 shares during the last quarter. ProShare Advisors LLC increased its position in Travere Therapeutics by 4.1% during the fourth quarter. ProShare Advisors LLC now owns 19,007 shares of the company’s stock worth $726,000 after purchasing an additional 756 shares during the last quarter. Allworth Financial LP purchased a new position in Travere Therapeutics during the second quarter worth approximately $47,000. Finally, Swiss National Bank raised its stake in Travere Therapeutics by 0.6% during the first quarter. Swiss National Bank now owns 168,100 shares of the company’s stock worth $4,994,000 after purchasing an additional 1,000 shares during the period.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts maintain a generally favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $68. Several firms have raised their targets to $70-$78, suggesting potential upside from recent trading levels. Travere Therapeutics analyst coverage
• Positive Sentiment: Institutional interest has increased, including new positions from Jupiter Topco and Bank of America, while Wellington Management and Perceptive Advisors expanded their holdings. The buying may reinforce confidence in Travere’s commercial prospects and rare-disease pipeline.
• Neutral Sentiment: Travere will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on FILSPARI and the company’s pipeline, although no new business information was announced. Travere presentation announcement
• Negative Sentiment: Multiple executives and insiders reported selling shares, including CEO Eric Dube, CFO Christopher Cline, CAO Sandra Calvin and several executive vice presidents. Collectively, the disclosed transactions represented roughly $61 million of stock sales, with individual holdings falling by approximately 6% to 60%. The trades were conducted under pre-arranged Rule 10b5-1 plans, which lessens their signaling value, but the concentration of selling may still weigh on investor sentiment and near-term momentum.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.